The influenza hemagglutinin (HA) is the major membraneassociated glycoprotein produced in cells as a result of influenza infection (1, 2). The molecule has served as a prototype for the study of intracellular protein assembly and transport (3). It plays an essential role in the initiation of influenza infection and in the pathogenicity of influenza A viruses (4). The influenza HA is also an important target for immune recognition. Several distinct regions on the mature HA molecule have been identified that are critical recognition sites for neutralizing antibody. These sites have been precisely localized to specific amino acid residues on the three-dimensional structure of HA (5- 
(CTL) generated in response to immunization with infectious type A influenza virus. Each of these sites can be mimicked by a synthetic oligopeptide of =2O amino acids. Data presented herein indicate that these two sites define the dominant immunogenic epitopes on the hemagglutinin recognized by H-2Kd-restricted CTL. These same sites are not efficiently recognized by hemagglutinin-specific class I MHC-restricted CTL of several unrelated MIIC haplotypes. These observations show that even for a large complex glycoprotein molecule like the influenza hemagglutinin, only a limited number of class I CTL recognition sites are generated in the infected cell and that the subset of immunogenic epitopes is dependent on the MHC haplotype of the responding individual. These parameters need to be considered in the design of synthetic and recombinant vaccines.
The influenza hemagglutinin (HA) is the major membraneassociated glycoprotein produced in cells as a result of influenza infection (1, 2) . The molecule has served as a prototype for the study of intracellular protein assembly and transport (3) . It plays an essential role in the initiation of influenza infection and in the pathogenicity of influenza A viruses (4) . The influenza HA is also an important target for immune recognition. Several distinct regions on the mature HA molecule have been identified that are critical recognition sites for neutralizing antibody. These sites have been precisely localized to specific amino acid residues on the three-dimensional structure of HA (5) (6) (7) . Furthermore, HA is a target antigen for T lymphocytes (8) (9) (10) including class I major histocompatibility complex (MHC)-restricted cytolytic T lymphocytes (CTL) (11) (12) (13) , which have been shown to play a positive role in recovery from influenza infection (14) (15) (16) .
Recently several lines of evidence have emerged that support the hypothesis that class I MHC-restricted CTL recognize nonnative (processed) forms of influenza HA and other viral antigens expressed on the surface of virally infected cells (17) (18) (19) . Antigen processing has been shown (20) to be a critical step in the presentation ofprotein antigens to class II MHC-restricted helper T lymphocytes. The class II MHC-linked genetic control of helper T-lymphocyte responsiveness to protein antigens is believed, in part at least, to reflect the direct interaction of processed antigens with specific class II MHC gene products (21, 22) . Accordingly, both the phenomenon of MHC restriction and the apparent immunodominance of certain sites on protein antigens recognized by class II MHC-restricted helper T lymphocytes may be dependent as well on the interaction of processed antigen with class II MHC molecules. In the case of class I MHC-restricted CTL, specific regions on viral (17) (18) (19) and cellular polypeptides (23, 24) have been identified as CTL recognition sites, but it is not known whether a limited number or a large number of distinct sites on a given viral antigen are available for recognition by class I MHCrestricted CTL. Here we examine the question of immunodominance of specific antigenic sites on a viral polypeptide in antigen recognition by murine CTL and the influence ofMHC haplotype on the immunodominance of antigenic sites.
MATERIALS AND METHODS
Mice. BALB/cByJ (H-2d) and CBA/J (H-2k) mice were purchased from The Jackson Laboratory.
Viruses. Influenza virus strains A/JAP/305/57 (H2N2 subtype) and B/LEE were grown in the allantoic cavity of 10-day-old chicken embryos. Infectious allantoic fluid was harvested 2 days later, and aliquots were stored at -70'C (25) . Vaccinia viruses were grown on CV-1 monkey kidney cell monolayers (American Type Culture Collection) infected with a multiplicity of infection of 0.01 and incubated at 37TC. On day 2, the CV-1 cells were pelleted, resuspended in a small volume, and subjected to three cycles of freezing/ thawing to release the virus particles from the cells. Preparations were plaqued on CV-1 monolayers to obtain titers. The vaccinia virus recombinant carrying the A/JAP/305/57 HA gene, designated VV(HA) (26) , was obtained from B. Moss (National Institutes of Health, Bethesda, MD). The vaccinia virus recombinants encoding the internal HA deletion mutants [designated VV(HAAXba) and VV(HAARI)J were generated in our laboratory by insertion at the vaccinia virus thymidine kinase (tk) locus using standard techniques (27) .
Cell Lines. The P815 (H-2d) mastocytoma cell line was maintained in Dulbecco's modified Eagle's (DME) medium (GIBCO) and supplemented with 10o (vol/vol) fetal bovine serum and 1% (wt/vol) glutamine. The LK35.2 (H_2kxd) cell solid-phase peptide synthesizer from Applied Biosystems (Foster City, CA).
Plasmids. Plasmid pSC11 (28) , which contains the 13-galactosidase gene linked to the vaccinia virus early promoter P11K and to the P7.5K promoter in opposite orientations was obtained from B. Moss. Plasmid pJHB16 (29) , which contains the wild-type A/JAP/305/57 HA gene, was obtained from M.-J. Gething (The Howard Hughes Medical Institute, University of Texas Health Science Center, Dallas).
T-Cell Clones. The cloned T lymphocytes used in this assay were derived from BALB/c or BALB/c x C57BL/6 F1 (CB6F1) mice. The procedures developed to establish and maintain them and an analysis of their viral specificity have been described in detail elsewhere (30, 31 were used as targets in standard 51Cr-release assays as described (25) . Cytotoxicity assays were carried out for 6 hr, and the resultant data were analyzed as described in detail (25) . For assays in which synthetic peptides were utilized, the peptides were diluted in assay medium to the appropriate concentrations and added to the clones and target cells in the 96-well microtiter plates. Generation of HA Gene Deletion Constructs. Plasmid pJHB16 contains the wild-type A/JAP/305/57 HA gene on a 1.9-kilobase (kb) HindIII/BamHI fragment. The HA gene contains two EcoRI and two Xba I restriction sites (see Fig.  1B ), which yield in-frame deletions. To generate the HA EcoRI deletion mutant (HAARI), the 1.9-kb HindIII/BamHI fragment of pJHB16 was introduced into the HincII site of pUC13, which lacked an EcoRI site in its polylinker. The resulting plasmid was digested with EcoRI, liberating a small 500-base-pair (bp) DNA fragment (corresponding to nucleotides 764-1264 of the HA gene) and religating the isolated large fragment. The resulting 1.4-kb HindIII/BamHI insert encoding the EcoRI deletion mutant was cloned into the Sma I site of plasmid pSC11. The HAARI construction encodes a mutant protein consisting of 398 amino acids and lacking amino acids 248-409 of the primary HA translation product. The HA Xba I deletion mutant (HAAXba) was generated by digesting the original pJHB16 plasmid with Xba I to liberate the internal Xba I fragment corresponding to nucleotides 145-1327 of the HA gene and religating the isolated large fragment. An 800-bp HindIII/BamHI insert encoding the HAAXba deletion mutant was isolated and inserted into the Sma I site of pSC11. The HAAXba construction encodes a mutant protein consisting of 166 amino acids and lacking HA residues 35-428.
RESULTS AND DISCUSSION
Recognition of HA Sites by Cloned Class I MHC-Restricted CTL. We have analyzed CTL recognition of influenza HA in mice of the H-2d MHC haplotype, using cloned CTL populations directed to the prototype HA derived from the A/JAP/305/57 (H2N2 subtype) virus. As part of our analysis of the fine specificity of CTL recognition, we have identified two sites on the A/JAP/305/57 HA molecule that are recognized by H-2Kd-restricted CTL. One site is located in the hydrophobic transmembrane anchor domain of HA and can be mimicked by a short synthetic peptide corresponding to residues 523-545 of the HA protein (Fig. 1A) . This site was (Fig. 2) . This heterogeneous CTL population also recognized target cells treated with the HA-(523-545) peptide with similar efficiency, but these anti-viral CTL failed to recognize target cells treated with 20-mer amino acid peptides from two other regions of the A/JAP/305/57 HA corresponding to residues 299-321 and 316-340 (Fig. 2) . In contrast to the results in the H-2d haplotype, influenzaspecific CTL from CBA/J (H-2k haplotype) mice did not recognize histocompatible target cells treated with either the HA-(523-545) or the HA-(202-221) peptide. In this mouse strain, the influenza HA is an important class I CTL target antigen (11) (12) (13) (accounting for =30% of the total CTL response in our hands), and target cells expressing only the influenza HA gene product are efficiently lysed by heterogeneous influenza-specific CTL The efficient recognition of the HA-(202-221) and HA-(523-545) sites by both clonal and unselected heterogeneous populations of H-2d haplotype-restricted class I T lymphocytes suggested to us that these two sites on the HA molecule are immunodominant sites recognized by H-2d-restricted class I CTL. To further test the contribution of the HA-(202-221) and HA-(523-545) sites to the overall response to the HA molecule, we examined the capacity of unlabeled target cells treated with either the HA-(202-221) peptide or the HA-(523-545) peptide or with a mixture of both peptides, to compete with radiolabeled target cells for recognition and lysis of radiolabeled target cells by HA-specific class I CTL. For this analysis we used, as a source of HA-specific CTL, heterogeneous populations of cytotoxic effectors generated in response to immunization with infectious A/JAP/305/57 virus because infectious virus should stimulate the full range of HA-specific CTL. However, the CTL response to infectious influenza virus is heterogeneous and there are, in addition to HA-specific CTL, CTL directed to the nucleocapsid protein and other influenza viral gene products (34, 35) . Therefore, it was necessary to limit the analysis to the CTL subpopulation directed to the HA. To do so we used radiolabeled target cells expressing only the influenza HA gene product as a result of infection with a recombinant vaccinia virus vector containing the influenza A/JAP/305/57 HA gene (26) rather than influenza virus-infected target cells that would display all potential viral target antigens. P815 (H-2d) target cells treated with either the HA-(523-545) or HA-(202-221) peptides were able to partially inhibit lysis of HA-expressing labeled target cells (Fig. 3) The results with both CTL clones and heterogeneous populations of CTL indicated that the sites on the HA defined by these two synthetic peptides represent the primary regions of the A/JAP/305/57 HA recognized by H-2d-restricted class I CTL. Therefore, we wanted to know if the generation of these two sites de novo in an infected cell requires expression of the full-length HA gene product and concomitantly whether the formation of one site in the infected cell is dependent on the presence ofthe other site. To examine these questions, we expressed in P815 target cells two deletion mutants of the A/JAP/305/57 HA using recombinant vaccinia virus expression vectors. One of these mutants (HAARI) was generated by deletion of a 0.5-kb EcoRI fragment from the HA gene (Fig. 1B) . The resultant in-frame deletion mutant retains both the HA-(202-221) and the HA-(523-545) sites but lacks the coding sequence for 167 amino acids from residues 227 to 394 (EcoRI segment) of HA. P815 target cells expressing this HA deletion mutant are efficiently recognized by both HA-(202-221)-and HA-(523-545)-specific CTL clones (Table 1, experiment 3) . The second mutant (HAAXba) was generated by an in-frame deletion of a 1.1-kb Xba I fragment that spans the HA coding sequence from residues 20 thru 413, including the N-terminal HA-(202-221) site (Fig. 1B) . When expressed in histocompatible P815 target cells by using a recombinant vaccinia expression vector, the HAAXba mutant, which retains the HA-(523-545) anchor site, is efficiently recognized by anchor-specific CTL clones but not by CTL clones directed to the deleted HA-(202-221) site (Table 1, experiment 3) . These results indicate that the full-length HA gene product need not be expressed in the target cell for generation of the antigenic sites recognized by HA-specific CTL and that these antigenic sites can be expressed independently.
As a follow up to the analyses of recognition of the HAARI and HAAXba mutants by long-term cloned CTL, we tested whether these deletion forms of the HA molecule are efficiently recognized by heterogeneous populations of HAspecific CTL generated in response to infectious influenza virus. Both the HAARI and HAAXba were efficiently recognized by heterogeneous populations of H-2d-restricted CTL from BALB/c mice when expressed in histocompatible target cells by using recombinant vaccinia virus vectors (Fig.  4) . Proc. NatL. Acad. Sci. USA 86 (1989) HA genes in the target cells expressing the H-2k haplotype class I MHC products. Our data indicates that only a limited number of sites on the influenza HA glycoprotein are immunodominant for recognition by class I MHC-restricted CTL and that the location of these sites is dependent upon the haplotype of the class I MHC molecule seen in association with the HA antigenic epitope. That a nonnative (processed) form of HA is recognized by class I CTL is evidenced by several findings. First, the location of one of the antigenic sites at positions 523-545 within the hydrophobic transmembrane anchor domain of HA is incompatible with recognition of this site on the HA molecule in its native form. Also, the finding that the product of a mutant HA gene-i.e., HAAXbaI deletion gene, which encodes a polypeptide containing less than one-third of the amino acids present in the native glycoprotein-is still efficiently recognized by class I CTL argues against presentation of a native HA structure and favors recognition of a processed, possibly fragmented form of HA.
At present the basis for the dominance of two stretches of -20 amino acids at the N-and C-terminal portions of the 561-amino acid primary A/JAP/305/57 translation product is not yet clear. One attractive explanation for both the immunodominance of certain sites and the haplotype preference in site recognition by CTL is that class I MHC products of different haplotypes directly bind and present to CTL processed forms of HA in a haplotype-dependent fashion. Such direct interactions between processed antigens and MHC molecules have been directly quantitated for class II MHC molecules and synthetic peptides (21, 22) . The recent crystallographic data on the structure of a human class I MHC molecule are also consistent with the view that class I MHC molecules bind and present processed antigen to the antigen receptor on T lymphocytes (36) . Homology to some amino acid sequence motifs proposed to be characteristic of Tlymphocyte recognition sites on protein antigens was detected in the two immunodominant H-2d haplotype sites (37, 38) . This panel of clones with differing fine specificity of influenza HA recognition should be analyzed for the purpose of distinguishing which residues participate in MHC binding versus antigen receptor recognition (39) .
Results previously reported by Taylor et al. (40) for the influenza nucleoprotein similarly suggest that T-cell epitopes for a given haplotype are dictated in part by the class I MHC interaction with the specific determinant. Our results extend such observations to the HA molecule, which elicits both neutralizing antibodies and cell-mediated immune responses. Epitopes located either at a serologically polymorphic region [HA-(202-221)] or a conserved region [HA-(523-545)] of the HA molecule, while immunodominant for H-2Kd, are not immunogenic areas in a different haplotype. A similar inference can be drawn from recent work of Oldstone and co-workers (41, 42) , who have examined the response ofclass I MHC-restricted CTL to lymphocytic choriomeningitis virus polypeptides. One implication of these results is that, if there are similarities (motifs) shared among the various T-cell epitopes that would relate to MHC interaction, then these motifs should be distinct for individual MHC molecules.
Finally, our results raise important issues concerning strategies for the design of vaccines utilizing glycoprotein antigens like the influenza HA, which are major neutralizing antigens. Our results suggest that not only may there be a limited number of antigenic sites on such molecules recognized by class I CTL but also the location of these sites will be strongly influenced by the MHC type of the individual responding to the vaccine. In addition, our data imply that the sites recognized by antibody and class I CTL can be distinctly different. These issues must be taken into account in the design of synthetic vaccines for influenza, human immunodeficiency virus, and other important human pathogens.
